⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168090 | 0.90 | — | — | |
| SCHEMBL6167823 | 0.88 | PTGS1 (0.62) | — | |
| SCHEMBL6166783 | 0.85 | PTGS2 (0.62) | — | |
| SCHEMBL6168313 | 0.84 | PTGS1 (0.61) | — | |
| SCHEMBL6167608 | 0.84 | — | — | |
| SCHEMBL6168426 | 0.80 | PTGS1 (0.64) | — | |
| SCHEMBL6168717 | 0.80 | — | — | |
| SCHEMBL6166448 | 0.78 | — | — | |
| SCHEMBL6167548 | 0.78 | PTGS1 (0.61) | — | |
| SCHEMBL6391746 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233959-B1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PROD INC (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030236258-A1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-12-25 | — | — | US | disclosed |
| US-6531492-B1 | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | PFIZER INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1233959-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | Pfizer Products Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001040216-A1 | HETEROCYCLO-ALKYLSULFONYL PYRAZOLE DERIVATIVES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |